 Connection
Mayumi Nakagawa to Papillomavirus Vaccines
This is a "connection" page, showing publications Mayumi Nakagawa has written about Papillomavirus Vaccines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.424 |
|
|
|
-
Shibata T, Shah S, Evans T, Coleman H, Lieblong BJ, Spencer HJ, Quick CM, Sasagawa T, Stephens OW, Peterson E, Johann D, Lu YC, Nakagawa M. Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed. Front Immunol. 2021; 12:645299.
Score: 0.725
-
Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019 Aug; 78:8-16.
Score: 0.621
-
Ravilla R, Coleman HN, Chow CE, Chan L, Fuhrman BJ, Greenfield WW, Robeson MS, Iverson K, Spencer H, Nakagawa M. Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion. Integr Cancer Ther. 2019 Jan-Dec; 18:1534735419893063.
Score: 0.599
-
Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN. Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol. 2015 Jul; 22(7):679-87.
Score: 0.465
-
Stratton SL, Spencer HJ, Greenfield WW, Low G, Hitt WC, Quick CM, Jeffus SK, Blackmon V, Nakagawa M. A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine. Clin Trials. 2015 Jun; 12(3):199-204.
Score: 0.455
-
Wang X, Coleman HN, Nagarajan U, Spencer HJ, Nakagawa M. Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine. Vaccine. 2013 Dec 02; 31(49):5806-13.
Score: 0.418
-
Wang X, Che Y, Chen B, Zhang Y, Nakagawa M, Wang X. Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice. Int Immunopharmacol. 2018 Mar; 56:249-260.
Score: 0.141
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|